Catalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for RP2 + Opdivo in Uveal melanoma. The expected timing is based on the latest available company guidance and may change.
06/29/26:- REVEAL actively enrolling; Phase 2/3 transition remains expected in Q1 2027. 08/14/26:- REVEAL remains actively enrolling. Phase 2/3 transition is expected in Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.